skip to Main Content

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease


Brief Summary:

The reason for this study is to see how safe and effective the study drug donanemab is in
participants with early Alzheimer’s disease.


Inclusion Criteria:

– Gradual and progressive change in memory function reported by participants or
informants for ≥ 6 months

– MMSE score of 20 to 28 (inclusive) at baseline

– Meet 18F flortaucipir PET scan (central read) criteria

– Meet 18F florbetapir PET scan (central read) criteria

– Have a study partner who will provide written informed consent to participate

Exclusion Criteria:

– Contraindication to MRI or PET scans

– Current treatment with immunoglobulin G (IgG) therapy


  • North County Neurology Associates, Carlsbad, California, United States, 92011
  • Irvine Clinical Research Center, Irvine, California, United States, 92614
  • Pacific Research Network, San Diego, California, United States, 92103
  • Sharp Mesa Vista Hospital, San Diego, California, United States, 92123
  • Univ of California San Francisco, San Francisco, California, United States, 94158
Back To Top